Michael John Sumner - 26 Feb 2026 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Reporting relationship: Chief Medical Officer
Issuer ticker: INO
Reported as of: 26 Feb 2026
Net transaction value: -$6,986
SEC form: 4
Accepted by SEC: 27 Feb 2026, 16:47:13 UTC
Prior SEC filing: 01 Jul 2025
Next SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael John Sumner

Key filing fact

Michael John Sumner filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 27 Feb 2026.

Key facts

This page summarizes Michael John Sumner's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 27 Feb 2026, 16:47.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: -$6,986.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001936799 Primary reporting owner

Sumner Michael John

Relationship: Chief Medical Officer
Address: 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING
Signature: /s/ Michael John Sumner
Signature date: 27 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INO transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,010
Change %: +28%
Price
Shares after: 22,860
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F1

INO transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,550
Change %: +51%
Price
Shares after: 34,410
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F2

INO transaction

Common Stock

Tax liability

Transaction value: $6,986
Shares: -3,903
Change %: -11%
Price: $1.79
Shares after: 30,507
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INO transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -5,010
Change %: -50%
Price: $0.000000
Shares after: 5,009
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,010
Exercise price
Footnotes: F1

INO transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -11,550
Change %: -33%
Price: $0.000000
Shares after: 23,100
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,550
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 34,650 restricted stock units granted on February 27, 2025 was as follows: 11,550 shares vested on February 26, 2026; 11,550 shares will vest on February 26, 2027; 11,550 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Footnote F3

The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (2) herein.